Literature DB >> 32541904

Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice.

Annemarie B van der Aart-van der Beek1, Hiddo J L Heerspink2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32541904     DOI： 10.1038/s41581-020-0312-7

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  4 in total

1.  Endocrine system dysfunction and chronic heart failure: a clinical perspective.

Authors:  Giuseppe Lisco; Vito Angelo Giagulli; Michele Iovino; Roberta Zupo; Edoardo Guastamacchia; Giovanni De Pergola; Massimo Iacoviello; Vincenzo Triggiani
Journal:  Endocrine       Date:  2021-10-28       Impact factor: 3.925

2.  Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China.

Authors:  Hao Zhaohu; Huang Xiao; Shao Hailin; He Feng
Journal:  J Diabetes Res       Date:  2022-08-13       Impact factor: 4.061

3.  Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular p21 expression.

Authors:  Moh'd Mohanad Al-Dabet; Khurrum Shahzad; Ahmed Elwakiel; Alba Sulaj; Stefan Kopf; Fabian Bock; Ihsan Gadi; Silke Zimmermann; Rajiv Rana; Shruthi Krishnan; Dheerendra Gupta; Jayakumar Manoharan; Sameen Fatima; Sumra Nazir; Constantin Schwab; Ronny Baber; Markus Scholz; Robert Geffers; Peter Rene Mertens; Peter P Nawroth; John H Griffin; Maria Keller; Chris Dockendorff; Shrey Kohli; Berend Isermann
Journal:  Nat Commun       Date:  2022-08-27       Impact factor: 17.694

Review 4.  Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.

Authors:  Guntram Schernthaner; Naim Shehadeh; Alexander S Ametov; Anna V Bazarova; Fahim Ebrahimi; Peter Fasching; Andrej Janež; Péter Kempler; Ilze Konrāde; Nebojša M Lalić; Boris Mankovsky; Emil Martinka; Dario Rahelić; Cristian Serafinceanu; Jan Škrha; Tsvetalina Tankova; Žydrūnė Visockienė
Journal:  Cardiovasc Diabetol       Date:  2020-10-23       Impact factor: 9.951
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.